Abstract 17328: Novel Oral Anticoagulants in Adult Fontan Patients: A Multi-Site Experience
Amir Kazerouninia(Baylor College of Medicine), Wilson Lam(Princess Margaret Cancer Centre), Fred H. Rodriguez(Emory University Hospital), Benjamin P. Frischhertz(Vanderbilt University Medical Center), Ryan Byrne(Monroe Carell Jr. Children's Hospital), Justin Georgekutty(Northwell Health), Payton Kendsersky(Duke University), Dhaval R. Parekh(Baylor College of Medicine), Patricia Y. Chu(Vanderbilt University Medical Center), Peter Ermis(Baylor College of Medicine), Yunfei Wang(Central South University), Wayne Franklin(Baylor College of Medicine)
Cited by 0
Related Papers
Results of the FUEL Trial
|Circulation|2019|160
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92
Outcomes of Heart Failure-Related Hospitalization in Adults with Congenital Heart Disease in the United States
|Congenital Heart Disease|2012|91
Long-Term Outcomes After Atrial Switch Operation for Transposition of the Great Arteries
|Journal of the American College of Cardiology|2022|91
Clinical Outcomes of Adult Fontan-Associated Liver Disease and Combined Heart-Liver Transplantation
|Journal of the American College of Cardiology|2023|79